<DOC>
	<DOCNO>NCT01273519</DOCNO>
	<brief_summary>The purpose study ass whether adalimumab ( Humira® ) influence pain medication participant rheumatoid arthritis ( RA ) , psoriatic arthritis ( PsA ) ankylose spondylitis ( AS ) without comorbidities , constitute contraindication adalimumab state release summary product characteristic . Therefore shall evaluate pain medication use participant change , reduce stop due adalimumab treatment .</brief_summary>
	<brief_title>Assessment Pain Management Rheumatoid Arthritis , Psoriatic Arthritis Ankylosing Spondylitis Patients Who Are About Treated With Adalimumab</brief_title>
	<detailed_description>This non-interventional , observational study Humira ( adalimumab ) prescribe usual manner accordance term local marketing authorization regard dose , population indication . The assignment patient Humira-containing regimen decide advance current practice . The prescription Humira clearly separate decision include participant study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients age ≥ 18 year rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis Patients must fulfill international national guideline use biological disease modify antirheumatic drug rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis ( chest xray interferon gamma release assay purify protein derivativeskin test negative tuberculosis ) . In addition one follow criterion must fulfil : unsatisfactory disease modify antirheumatic drug response define failure treatment least two disease modify antirheumatic drug include Methotrexate patient rheumatoid arthritis psoriatic arthritis unsatisfactory non steroidal antiinflammatory drug response patient ankylose spondylitis unsatisfactory response prior biological disease modify antirheumatic drug patient rheumatoid arthritis psoriatic arthritis ankylose spondylitis Patients meet contraindication outline late version Humira syringe® summary product characteristic Humira Pen® summary product characteristic Patients participate another study program clinical trial Patients treat Humira</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Ankylosing</keyword>
	<keyword>Rheumatoid</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Pain</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Psoriatic</keyword>
	<keyword>Spondylitis</keyword>
	<keyword>Monoclonals</keyword>
</DOC>